Can BridgeBio’s Attruby narrow Pfizer’s Vyndamax lead in the ATTR-CM market?
Pfizer owns the ATTR-CM legacy. BridgeBio now has data that could test whether clinical differentiation can move prescribing habits.
Can Alnylam’s AMVUTTRA become a first-line treatment force in ATTR-CM?
ATTR-CM treatment is shifting earlier. Alnylam must now prove AMVUTTRA can win clinician trust beyond trial subgroups.
How Alnylam Pharmaceuticals is using new ACC.26 data to deepen the case for vutrisiran and zilebesiran
See why Alnylam Pharmaceuticals’ new ACC.26 data on vutrisiran and zilebesiran could reshape cardiovascular strategy and market expectations.